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Abstract
Background: In the UK, 1–2% of infants are born very preterm (<32 weeks of gestation) or have very low birth weight
(<1500 g). Very preterm infants are initially unable to be fed nutritional volumes of milk and therefore require
intravenous nutrition. Milk feeding strategies influence several long and short term health outcomes including growth,
survival, infection (associated with intravenous nutrition) and necrotising enterocolitis (NEC); with both infection and
NEC being key predictive factors of long term disability. Currently there is no consistent strategy for feeding preterm
infants across the UK. The SIFT trial will test two speeds of increasing milk feeds with the primary aim of determining
effects on survival without moderate or severe neurodevelopmental disability at 24 months of age, corrected for
prematurity. The trial will also examine many secondary outcomes including infection, NEC, time taken to reach full
feeds and growth.
Methods/design: Two thousand eight hundred very preterm or very low birth weight infants will be recruited from
approximately 30 hospitals across the UK to a randomised controlled trial. Infants with severe congenital anomaly or
no realistic chance of survival will be excluded. Infants will be randomly allocated to either a faster (30 ml/kg/day) or
slower (18 ml/kg/day) rate of increase in milk feeds. Data will be collected during the neonatal hospital stay on
weight, infection rates, episodes of NEC, length of stay and time to reach full milk feeds. Long term health
outcomes comprising vision, hearing, motor and cognitive impairment will be assessed at 24 months of age
(corrected for prematurity) using a parent report questionnaire.
Discussion: Extensive searches have found no active or proposed studies investigating the rate of increasing milk
feeds. The results of this trial will have importance for optimising incremental milk feeding for very preterm and/
or very low birth weight infants. No additional resources will be required to implement an optimal feeding strategy,
and therefore if successful, the trial results could rapidly be adopted across the NHS at low cost.
Trial registration: ISRCTN Registry; ISRCTN76463425 on 5 March, 2013.
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Background
Outcomes affected by feeding strategies
In the UK, 1–2% of newborn infants are very preterm or
have very low birth weight. Preterm birth is the major
risk factor for infant mortality, with 73% of neonatal
deaths in the UK occurring in infants born before 37
completed weeks of gestation [1]. As survival, especially
of very preterm infants, has increased in recent years
[2], the high prevalence of morbidity associated with
preterm birth means that the assessment of long-term
outcomes has become increasingly important [3].
Short and long-term outcomes for preterm infants are
affected by strategies that reduce infection rates, lower
NEC rates, promote adequate growth, and maintain ac-
cess to tertiary level facilities. Optimising feeding strat-
egies affects all of these outcomes. Benefits are therefore
likely to arise both from the individual and combined ef-
fects of identifying the optimum feeding strategy, as the
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rates of such complications in very preterm infants are
high. NEC severe enough to cause death or require sur-
gery affects approximately 7.5% of infants born before
29 weeks gestation, and is the cause of death in 11% of
the deaths of infants born before 32 weeks [4]. Late-
onset infection affects around 25% of very preterm in-
fants and is responsible for 10% of deaths in the same
population. Long-term data following late onset infec-
tion or NEC suggest these conditions almost double the
risk of poor neurodevelopmental outcome [5].
Nutritional support of preterm infants and speed of
increasing milk feeds
Every year in the UK around 8000 infants are born so
preterm that they cannot initially be fed milk and there-
fore require intravenous nutrition. Milk feeding is grad-
ually increased as the immature gut begins to tolerate
milk and intravenous nutrition is correspondingly re-
duced, but there are few data determining how quickly
this is best achieved [6].
One of the most serious complications of intravenous
feeding is late-onset sepsis, which occurs in 27% of in-
fants born weighing less than 1500 g at birth or under
29 weeks’ gestation [6]. Late-onset sepsis is known to
cause poor long-term cognitive outcomes, liver damage
and also sudden death from cardiac problems resulting
from misplaced catheters [7–9]. One of the most com-
mon late-onset infections is ‘catheter-related blood-
stream infection’; the risk of bloodstream infection being
directly related to the time the catheter is indwelling in
the bloodstream [10–12].
The more rapid advancement of enteral feeds de-
scribed in this study will, in principle, reduce exposure
to intravenous nutrition by causing infants to reach full
milk feeds (tolerating 150 ml/kg/day for 3 consecutive
days) about 4 days earlier than the slower advancement.
Reducing exposure by this amount could reduce the
number of infections by between 5 and 15 cases per 250
infants, which is an absolute risk reduction of 4%. This
is possibly an underestimate of the reduction as infec-
tion risk increases with the length of time a catheter is
in place [13, 14].
However, faster increases in milk feed volumes may in-
crease the likelihood of NEC which, as well as being po-
tentially fatal, may provoke intolerance of feeds or gut
dysfunction that could result in longer times to achieve
full feeds rather than shorter. Survivors of NEC also have
significantly worse long-term outcomes across multiple
developmental domains than those unaffected [5, 15].
Therefore, while emerging data suggest better health
outcomes may be achieved with faster feeding increments,
there are possible disadvantages and a randomised con-
trolled trial is required to support a change in clinical
practice [6].
Trial objectives
The primary objective of the trial is to compare the ef-
fects of two speeds of increasing milk feeds on survival
without moderate or severe disability at 24 months of
age (corrected for prematurity). The secondary objec-
tives are to assess the impact of the two speeds of in-
creasing milk feeds on the incidence of sepsis and
NEC, and other outcomes collected before hospital
discharge.
Methods/design
The trial is a multi-centre randomised controlled group
trial (RCT) to assess whether the speed of increasing
milk feed volumes (faster increase [30 ml/kg/day] versus
slower increase [18 ml/kg/day]) in very preterm (<32 weeks)
or very low birth weight infants (<1500 g) infants has any
effect on survival without moderate or severe disability at
24 months corrected age.
Two thousand eight hundred infants from approxi-
mately 30 neonatal units will be recruited within the UK
and Ireland over 3 years.
Inclusion criteria
 Gestational age at birth is <32 completed weeks, or
birth weight <1500 g
 Receiving ≤30 ml/kg/day of milk at randomisation
 Written informed parental consent is obtained
Exclusion criteria
 Severe congenital anomaly
 In the opinion of the treating clinician, have no
realistic chance of survival
 Unlikely to be traceable for follow-up at 24 months
of age (for example, infants of non-UK residents)
Primary outcome
The primary outcome will be the proportion of infants
surviving without moderate or severe neurodevelop-
mental disability at 24 months of age corrected for pre-
maturity. This composite outcome will be determined
by confirming that the child is alive or dead using re-
cords held and maintained by The Health and Social
Care Information Centre and other central UK NHS
bodies. For live infants, a parent report questionnaire
will be used to assess sensory and gross motor impair-
ment and standardised measures to assess cognitive
function in order to identify children with:
 Moderate/severe visual impairment (reduced vision
uncorrected with aids; or blind in one eye with good
vision in the contralateral eye; or blind/perceives
light only)
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 Moderate/severe hearing impairment (hearing loss
corrected with aids; or some hearing loss but not
corrected by aids; or deaf )
 Moderate/severe gross motor impairment (unable to
walk or sit independently)
 Moderate/severe cognitive impairment assessed
using the Parent Report of Children’s Abilities–Revised
(PARCA–R), a parent report measure of non-verbal
cognitive and language development. Total PARCA–R
scores <44 will be used to identify children with
moderate/severe cognitive impairment [16]. This
questionnaire has been shown to have at least 80%
sensitivity and 80% specificity for identifying children
with scores < −2SD on a Gold Standard development
test [16, 17]
A child who has any one or more of these impair-
ments will be classified with a moderate/severe disability.
Definitions for motor and sensory impairments described
above are as defined in the report published by British
Association of Perinatal Medicine (BAPM) in 2008 [18].
Secondary outcomes
Secondary outcomes to be assessed when infants are dis-
charged home for the first time are:
 Survival to discharge home.
 Microbiologically-confirmed or clinically suspected
late-onset invasive infection from trial entry to
discharge home.
 NEC (Bell stage 2 or 3) from trial entry to discharge
home.
 Time taken to reach full milk feeds (tolerating
150 ml/kg/day for 3 consecutive days).
 Growth (change in z score–weight and head
circumference for gestational age) from birth to
discharge home.
 Duration of parenteral feeding.
 Length of time in intensive care.
 Length of hospital stay to discharge home.
In addition, the separate components of the composite
primary outcome at 24 months of age corrected for pre-
maturity will be analysed individually as secondary out-
comes. The diagnosis of cerebral palsy by a doctor or
other health professional will also be a secondary out-
come assessed at this age.
Trial procedures
Informed consent
Written consent will be sought from parents only after
they have been given a full verbal explanation and writ-
ten description of the trial via a parent information leaf-
let. Consent will be obtained by means of dated parental
signature on a study consent form and the signature of
the person who obtained informed consent. Recruitment
will be conducted by a health professional with delegated
authority. Parents who do not speak English will only be
approached if an interpreter is available.
Remuneration
Parents will not be given any financial or material incen-
tive or compensation for enrolling their babies in this
trial.
Randomisation and allocation
Randomisation will take place at the time the clinician is
ready to start increasing the feed volume. This will be per-
formed through a secure website hosted by the NPEU
CTU with telephone back-up available 24/7, 365 days a
year.
A minimisation algorithm will be used to ensure balance
on important prognostic factors: hospital, multiple birth,
gestational age ranges, and birth weight <10th centile for
gestational age. Multiple births will be given the same
allocation.
Blinding
This is an open trial; blinding of the clinicians, nursing
staff, and parents is not possible. A blinded endpoint re-
view committee will examine the relevant data collection
forms and clinical notes of infants with possible sepsis
and NEC and classify them systematically according to
predefined criteria.
Stopping or modifying the trial intervention
Deviations from the scheduled speed of increase may be
made at the discretion of the treating clinician if the in-
fant appears unable to tolerate the allocated speed of
milk feed increase.
Withdrawal
At all stages it will be made clear to the parents that they
are free to withdraw their infant from the trial at any time,
without the need to provide explanation. If parents choose
to withdraw, they will be asked for permission to complete
data collection and/or follow-up.
The attending clinician may also withdraw the infant
from the allocated treatment if they consider this to be
in the best interest of the infant’s health and well-being.
Data collection before discharge
All outcome data are routinely recorded clinical items that
can be obtained from the clinical notes or local microbio-
logical laboratory records. No additional blood or tissue
samples are required for this trial. Clinical information will
be collected using specially created data collection forms.
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Data collection after discharge
A parent questionnaire will assess neurodevelopmental out-
comes and health care costs when the infant is 24 months
of age (corrected for prematurity).
Data collection and processing
Data will be processed using validated data management
systems to ensure consistency, viability and quality of
data. It will be stored in line with the Data Protection
Act 1998.
Safety reporting
Adverse events are defined as serious if they:
 Result in death
 Are life-threatening
 Require inpatient hospitalisation or prolongation of
existing hospitalisation
 Result in persistent or significant disability/incapacity,
or
 Are a congenital anomaly/birth defect
The term “life-threatening” refers to an event in which
the child was at risk of death at the time of the event; it
does not refer to an event which hypothetically might
have caused death if it were more severe. SAEs are to be
reported from randomisation until discharged home.
Safety reporting will be carried out in accordance with
the NPEU Clinical Trials Unit standard operating proce-
dures and clinical regulations.
Sample size and power
The primary comparison will be the difference in the
proportion of infants surviving without moderate or se-
vere disability at 24 months of age corrected for prema-
turity. Based on previous trials, it is estimated that 80%
of the infants will survive to 2 years, and that 11% of
these will have a moderate or severe disability [19].
Hence it is estimated the proportion surviving without
moderate or severe disability in the control group receiv-
ing the 18 ml/kg/day increment will be 71%. With a total
sample size of 2500 and allowing for a response rate of
80%, there will be 90% power to detect an absolute dif-
ference of 6.3% (from 71.0% in the control group to
77.3%) in this proportion, with a two-sided 5% signifi-
cance level.
With the same level of significance, a sample size of
2500 infants will have 90% power to detect an absolute
risk difference of 5.4% (from 25.0% in control group to
19.6%) in the incidence of sepsis [20] and an absolute
risk difference of 3.5% (from 6.0% in control group to
9.5%) in the incidence of NEC (Bell stage 2 or 3) [21–23].
An inflation factor of 1.12 was applied to the sample
size to allow for multiple births, expected to have
correlated outcomes, receiving the same allocation. This
was based on an estimate of 25% for the proportion of
multiple births and an intraclass correlation coefficient
of 0.9 for the primary outcome at 2 years, based on a
similar outcome in a preterm population [24]. The total
number of babies that will be recruited will be 2800.
Statistical analysis
Demographic factors, clinical characteristics and out-
comes will be summarised with counts (percentages) for
categorical variables, mean (standard deviation) for
Normally distributed continuous variables, or median
(interquartile or entire range) for other continuous var-
iables. Infants will be analysed according to allocation
regardless of the speed of milk feed increase they actu-
ally receive.
The two groups will be compared using generalised es-
timating equations, adjusting for the minimisation fac-
tors to account for the correlation between treatment
groups. This method of analysis will also account for the
correlation in outcomes between twins and siblings born
in a subsequent pregnancy during the trial period. For
the primary outcome, an adjusted risk ratio with 95%
confidence will be calculated using log binomial regres-
sion, or log poisson regression with a robust variance es-
timator if the binomial model fails to converge [25].
Linear regression will be used for Normally distributed
outcomes, quantile regression for skewed continuous vari-
ables, and Cox regression for time to event outcomes.
Ninety-nine percent confidence intervals will be calculated
for all secondary outcomes.
The consistency of the effect of advancing milk feeds
across specific subgroups of infants will be assessed using
the statistical test of interaction. Pre-specified subgroup
analyses include: (i) week of gestation at birth, (ii) birth
weight (<10th centile for gestational age versus ≥ 10th
centile and (iii) type of milk (breast milk only/formula
only/mixed). Subgroup analysis will be performed on
the primary outcome, and the incidence of sepsis and
NEC.
Economic data collection
Relevant resource use data collection will be undertaken
prospectively from centres participating in the trial. Pri-
vate out of pocket costs to parents will be collected via a
questionnaire sent at 24 months of age corrected for
prematurity. Unit costs will be obtained from published
sources and centres participating in the trial and applied
to resource use. Published sources will include Unit
Costs of Health and Social Care [26] and NHS Reference
Costs.
The main economic analysis will be in the form of a
cost-effectiveness analysis from the perspective of the
health care provider (National Health Service), based on
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an intermediate outcome of cost per neonatal sepsis
avoided when discharged home and on the outcome of
disability-free survival at 24 months of age corrected for
prematurity (cost per additional survivor without disabil-
ity at 24 months of age corrected for prematurity). A
secondary analysis will extend the perspective to include
private out of pocket costs to families associated with
travel and time off work during the period of follow up.
The analyses will adopt an incremental approach in
that data collection will concentrate on resource use and
outcome differences between trial arms. A bootstrapping
approach will be undertaken in order to calculate confi-
dence intervals around the mean costs [27, 28]. Costs
and benefits will be discounted as per NICE guidelines
at 3.5%.
Results will be presented using cost-effectiveness ac-
ceptability curves. The robustness of the results will be
explored using deterministic and probabilistic sensitivity
analysis.
Discussion
Preterm infants are at significant risk of poor long-term
neurodevelopmental problems with almost 12% having
moderate or severe disability [19], with both sepsis and
NEC dramatically increasing this risk [29–34]. Achieving
full milk feeding sooner is associated with significant cost
savings through decreased use of intravenous nutrition, a
reduction in time spent in a specialist tertiary neonatal
unit, shortened total hospital stay (potentially saving
£1000 per day), and reductions in societal costs due to im-
proved long-term outcomes [29–34]. Vacating tertiary
level neonatal cots sooner will also improve the family’s
experience and the infant’s safety by decreasing the need
for transfer to other hospitals for intensive care.
Infection and NEC remain highly predictive factors for
neurodevelopmental disability. Any reduction in either
problem may therefore be expected to reduce long-term
disability in this population.
Overall lifetime financial costs of disability are signifi-
cant, and so preventing even a few cases and reducing
cognitive problems at the population level would reduce
the financial burden of long-term care for the NHS and
society. No additional resources will be needed to imple-
ment the optimal feeding strategy, which, if successful,
could be adopted rapidly across the NHS at low cost.
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